Stock Scorecard
Stock Summary for INmune Bio Inc (INMB) - $11.60 as of 5/2/2024 1:56:13 PM EST
Total Score
6 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for INMB
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for INMB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for INMB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for INMB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for INMB
Financial Details for INMB
Company Overview |
|
|---|---|
| Ticker | INMB |
| Company Name | INmune Bio Inc |
| Country | USA |
| Description | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/31/2024 |
Stock Price History |
|
| Last Day Price | 11.60 |
| Last Day Price Updated | 5/2/2024 1:56:13 PM EST |
| Last Day Volume | 243,186 |
| Average Daily Volume | 148,836 |
| 52-Week High | 14.74 |
| 52-Week Low | 6.50 |
| Last Price to 52 Week Low | 78.46% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 60.82 |
| Sector PE | 53.36 |
| 5-Year Average PE | -6.69 |
| Free Cash Flow Ratio | 6.07 |
| Industry Free Cash Flow Ratio | 19.61 |
| Sector Free Cash Flow Ratio | 30.86 |
| Current Ratio Most Recent Quarter | 2.16 |
| Total Cash Per Share | 1.91 |
| Book Value Per Share Most Recent Quarter | 2.08 |
| Price to Book Ratio | 4.91 |
| Industry Price to Book Ratio | 7.49 |
| Sector Price to Book Ratio | 22.00 |
| Price to Sales Ratio Twelve Trailing Months | 1,208.36 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.43 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.14 |
Share Statistics |
|
| Total Shares Outstanding | 18,775,000 |
| Market Capitalization | 217,790,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -9.92% |
| Reported EPS 12 Trailing Months | -1.67 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -1.67 |
| Net Income Twelve Trailing Months | -30,008,000 |
| Net Income Past Year | -30,008,000 |
| Net Income Prior Year | -27,299,000 |
| Quarterly Revenue Growth YOY | -71.10% |
| 5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 35,848,000 |
| Total Cash Past Year | 35,848,000 |
| Total Cash Prior Year | 52,153,000 |
| Net Cash Position Most Recent Quarter | 20,927,000 |
| Net Cash Position Past Year | 20,927,000 |
| Long Term Debt Past Year | 14,921,000 |
| Long Term Debt Prior Year | 15,000,000 |
| Total Debt Most Recent Quarter | 14,921,000 |
| Equity to Debt Ratio Past Year | 0.71 |
| Equity to Debt Ratio Most Recent Quarter | 0.71 |
| Total Stockholder Equity Past Year | 37,340,000 |
| Total Stockholder Equity Prior Year | 60,104,000 |
| Total Stockholder Equity Most Recent Quarter | 37,340,000 |
Options |
|
| Put/Call Ratio | 0.02 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.26 |
| MACD Signal | -0.48 |
| 20-Day Bollinger Lower Band | 9.28 |
| 20-Day Bollinger Middle Band | 11.63 |
| 20-Day Bollinger Upper Band | 13.98 |
| Beta | 1.95 |
| RSI | 57.48 |
| 50-Day SMA | 9.59 |
| 200-Day SMA | 10.86 |
System |
|
| Modified | 5/2/2024 3:07:18 AM EST |